Advertisement

Topics

Top five promising drugs (November 2013)

05:57 EDT 22nd September 2017 | BioPortfolio

THE FIVE MOST PROMISING DRUGS LAUNCHED OR RECEIVING APPROVAL

DRUG DISEASE COMPANY
Gilotrif™ (afatinib) Non-small-cell lung cancer (NSCLC) Boehringer Ingelheim
Typbar-TCV Typhoid Bharat Biotech International
Mirvaso® (brimonidine) Rosacea-associated erythema Galderma
Alzumab™ (Itolizumab) Psoriasis Biocon Biopharmaceuticals
Adempas® (riociguat) Chronic thromboembolic pulmonary hypertension Bayer


  
 
  
  
  

 


Topics to Watch

  • Orphan Drug – Boehringer Ingelheim’s Gilotrif™ granted Orphan Drug designation in December 2011 binds irreversibly to EGFR/HER1, HER2 and HER4, targeted at patients exhibiting EGFR-mutations. Gilotrif was approved in July 2013 in the U.S. as a first-line treatment for EGFR-mutated NSCLC.
  • Global First-in-Class Drug – Biocon Biopharmaceuticals’ Alzumab™ was launched in August 2013 for the treatment of chronic plaque psoriasis. This humanized monoclonal antibody represents a global first-in-class CD6 inhibitor.
  • Chronic thromboembolic PH (CTEPH) – Bayer’s Adempas® an oral sGC stimulator, is the first drug to be approved for the treatment of CTEPH. According to forecast data from Cortellis™ Competitive Intelligence, sales of Adempas will reach $578 million in 2017.  

Source: Thomson Reuters Cortellis Competitive Intelligence

Quick Search
Advertisement
 

review and buy Top five promising drugs (November 2013) market research data and corporate reports here